The artificial intelligence (AI)-powered EchoGo Amyloidosis can reportedly detect cardiac amyloidosis by assessing a single echocardiogram.
The Food and Drug Administration (FDA) has granted Breakthrough Device Designation for EchoGo Amyloidosis (Ultromics), which provides artificial intelligence (AI) assessment of echocardiograms to help diagnose cardiac amyloidosis.
While cardiac amyloidosis can be challenging to diagnose due to a heterogenous array of subtypes, including ATTR amyloidosis (transthyretin amyloidosis) and AL amyloidosis (light chain amyloidosis), Ultromics said the EchoGo Amyloidosis modality (developed with support from Janssen Biotech, Inc.) can detect the condition based on one echocardiogram.
Ultromics and Janssen Biotech said the EchoGo Amyloidosis platform is an important innovation in diagnosing a disease that has five-year mortality rates ranging from 44 to 65 percent without early detection.
“While treatments exist to help slow or halt the progression of cardiac amyloidosis, underdiagnosis in the early stages of disease is a huge challenge,” noted Najat Khan, Ph.D., the chief data science officer and global head of Strategy and Operations at Janssen Research and Development, LLC. “When applied to routine tests like echocardiograms, artificial intelligence is demonstrating exciting potential to help facilitate earlier disease detection with the goal of connecting patients with treatment sooner and, ultimately, driving better health outcomes.”
Ultromics noted that EchoGo Amyloidosis platform is intended to be included within the company’s EchoGo Platform. Currently in the midst of preparing regulatory submission of the modality, Ultromics said the EchoGo Amyloidosis platform could receive clearance for commercialization by early 2024.
(Editor’s note: For related content, see “Study Finds AI More Effective Than Sonographer Interpretation of Cardiac Function on Echocardiograms” and “Adjunctive AI Software for Cardiac Ultrasound Gets FDA Nod.”)
New AI-Powered Ultrasound Devices May Enhance Efficiency in Women's Imaging
April 19th 2024One of the features on the new Voluson Signature 20 and 18 ultrasound devices reportedly uses automated AI tools to facilitate a 40 percent reduction in the time it takes to perform second trimester exams.
Could a Deep Learning Model for Mammography Improve Prediction of DCIS and Invasive Breast Cancer?
April 15th 2024Artificial intelligence (AI) assessment of mammography images may significantly enhance the prediction of invasive breast cancer and ductal carcinoma in situ (DCIS) in women with breast cancer, according to new research presented at the Society for Breast Imaging (SBI) conference.
The Reading Room: Artificial Intelligence: What RSNA 2020 Offered, and What 2021 Could Bring
December 5th 2020Nina Kottler, M.D., chief medical officer of AI at Radiology Partners, discusses, during RSNA 2020, what new developments the annual meeting provided about these technologies, sessions to access, and what to expect in the coming year.
AI Adjudication Bolsters Chest CT Assessment of Lung Adenocarcinoma
April 11th 2024The inclusion of simulated adjudication for resolving discordant nodule classifications in a deep learning model for assessing lung adenocarcinoma on chest CT resulted in a 12 percent increase in sensitivity rate.